Terminated PHASE1 INTERVENTIONAL NCT00060294

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Phase I Study of Zevalin (90Y-Ibritumomab Tiuxetan) in Waldenstrom's Macroglobulinemia (Lymphoplasmacytic Lymphoma)

Sponsor: Jonsson Comprehensive Cancer Center

Conditions Lymphoma

Interventions rituximab yttrium Y 90 ibritumomab tiuxetan

Updated 6 times since 2017 Last updated: Jan 7, 2013 Started: Apr 30, 2003 Primary completion: Jun 30, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

no accrual

Other terminated trials from Jonsson Comprehensive Cancer Center

See all terminations from Jonsson Comprehensive Cancer Center

Other Lymphoma trials with similar outcome

Browse all Lymphoma trials

This PHASE1 trial investigates Lymphoma and is currently terminated or withdrawn. Jonsson Comprehensive Cancer Center leads this study, which shows 6 recorded versions since 2003 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE1
Feb 2017 — Jun 2018 [monthly]

Terminated PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Terminated PHASE1

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Data source: Jonsson Comprehensive Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States
• Los Angeles, United States